Pfizer Ends Funding to Alzheimer’s and Parkinson’s Research — The Fallout for Neurology
Pfizer, one of the largest pharmaceutical companies in the world, announced in January that it would end all funding for research in Parkinson’s disease and Alzheimer’s disease, taking researchers by surprise.
Pfizer will continue to commit resources to late-stage development programs for Lyrica (pregabalin) for diabetic nerve pain, and for tanezumab, a drug being tested in osteoarthritis pain, as well as back and cancer pain. It also said it would continue funding research on drugs for rare neuromuscular and neurological diseases.
© 2018 American Academy of Neurology